Drug Development, Treatment, Artificial Intelligence, Molecule Engineering and Innovation
Company
Platform
Pipeline
News
Contact
Investors
Community
OUR STORIES
Medicines matter in everyone's lives
What we’re building can make a real difference
Verseon: Combining Deep Quantum Modeling™ and AI to Find Breakthrough Drugs
Verseon’s CEO Adityo Prakash discusses the role of the company’s Deep Quantum Modeling™ of protein-drug interactions with Pharmaceutical Executive’s Mike Hollan
April 14, 2025
VersAI's Unique Neural Network Architecture Marks a Major Leap Forward for Drug Discovery AI
Drug Discovery World's editor Reece Armstrong and Verseon's CEO Adityo Prakash discuss the implications of different AI neural network architectures for drug discovery
March 25, 2025
VersAI is More Accurate and Orders of Magnitude Faster than Google's AutoML
Verseon is challenging the dominance of deep learning—especially in areas where data is scarce
February 9, 2025
A Pharma Company (Really?) Leading the Way in AI Innovation? Yes, Really!
Using a novel neural "network of networks" architecture, VersAI™ trains models 3,000 times faster than Google AutoML on standard benchmark datasets
January 21, 2025
From Months to Minutes: VersAI™ Sets New Standard for AI Training Speed
Verseon's novel general-purpose AI technology shows dramatically faster training speeds compared to Deep Learning technologies like Google's AutoML
December 19, 2024
How Organoids Will Impact Medicine
Verseon's Head of Discovery Biology Anirban Datta discusses how recent breakthroughs are bringing once-distant possibilities for drug discovery and restoration of organ function closer to reality
October 30, 2024
How Verseon's AI Overcomes Data Scarcity to Transform Medicine
Verseon's newly developed AI technology, VersAI™, elevates AI accuracy in drug discovery - even with sparse data
October 29, 2024
Forbes Highlights Verseon's Platform to Design Novel Drugs No One Else Can
"Verseon's disruptive platform changes how drugs can be discovered and developed, and the company is poised to make a dramatic impact on modern medicine."
October 22, 2024
Verseon Develops Superior Approach in Combining AI Models for Greater Accuracy
Peer-reviewed paper describes novel ensembling technique that offers 150% improvement over current state of the art
October 9, 2024
VersAI™ : Ensuring AI Accuracy When Data Is Sparse
Verseon’s newly developed technology elevates AI accuracy to a new level, overcoming the major challenge sparse data poses in drug discovery and many other fields
October 2, 2024
A Quiet Revolution: The Global Race to Control Human Biology and Its Implications
The United States is locked in a quiet but heated race for bioscience and biotechnology supremacy with China. It is a race that changes everything
September 30, 2024
Verseon: the Future of Drug Discovery
CEO Adityo Prakash discusses the impact of Verseon’s innovations in AI, physics, and drug discovery on the future of medicine
September 18, 2024
33 Zeroes: Verseon Advances AI Accuracy for Novel Small Molecule Designs
How new tech unlocks seemingly infinite chemical space
September 12, 2024
Announcing VersAI™: Setting a New Standard for AI Accuracy
"Beyond drug discovery, VersAI's greater accuracy and lower error rates can dramatically improve the utility and reliability of AI in our everyday lives."
September 11, 2024
Drug Discovery AI Not Living Up to the Hype
Small-molecule drug discovery is hard. AI was supposed to make it easier. But it hasn't. What happened?
September 10, 2024
The Current State of Predicting Mortality and Disease
In a comprehensive systematic review of age-measurement literature, Verseon team members assess applicability, limitations, and clinical utility of epigenetic and phenotypic clocks
August 30, 2024
Verseon and NeuTherX Announce Partnership to Enhance Drug Development
Innovative technologies to improve drug-candidate selection and clinical-trial design
July 30, 2024
CEO Adityo Prakash Describes How Verseon Overcame AI’s Data Limitations Using Quantum Physics Modeling
"What we have found at Verseon is that marrying physics with AI… allows you to efficiently explore the uncharted chemical ocean of possibilities to find the drugs of the future."
June 24, 2024
CEO Adityo Prakash Discusses How Verseon Overcame the Pitfalls of AI in Drug Discovery with A Geek Leader's John Rouda
"In small-molecule drug discovery AI clearly has a very big data problem. But you can get around this data problem if you combine AI with… breakthroughs in quantum physics."
May 24, 2024
Healthcare IT Today Discusses How Verseon Uses AI to Gain Additional Insights from Clinical-Trial Data
Verseon's analysis of patient data collected during clinical trials adds significant additional insight into progression of disease conditions and effects of therapeutic intervention.
May 22, 2024
Verseon's Drug Candidates Promise Hereditary Angioedema Treatment with Fewer Risks and Lower Cost
Examining previously inaccessible drug-like compounds with Deep Quantum Modeling opens the door to breakthrough medicines that offer better outcomes to patients
April 23, 2024
Verseon CEO Adityo Prakash Discusses AI in Healthcare with Health Connective
Current drug-discovery AI lacks actionable data. But Verseon combined its breakthroughs in quantum physics with its proprietary explainable AI to find drugs poised to change the standard of care for major human diseases.
April 9, 2024
Will AI Impact Healthcare Costs?
Verseon CEO Adityo Prakash tells ABC News, "AI will make healthcare delivery more efficient. But a major factor that determines cost... is human greed. Unfortunately, AI can’t help us there."
April 8, 2024
The Future of Pharma Is Deep Quantum Modeling
Verseon CEO Adityo Prakash discusses systematically creating era-defining treatments with California Business Journal
March 1, 2024
The Future of AI in the Pharma Industry
Verseon CEO Adityo Prakash discusses the present and future of AI in the pharma industry with NBC News
February 2, 2024
US Patent Issued for Verseon PROAC
Drug candidate promises to greatly improve standard of care for several hundred million cardiovascular patients
January 24, 2024
Verseon Charts the Unknown with Physics and AI
What the world needs are fundamentally novel treatments with new therapeutic profiles
December 20, 2023
Verseon Pioneers Real-time Explainable AI
Revolutionary approach gives robust insights in real time into how AI models reach decisions
December 7, 2023
Nobel Laureate Hartmut Michel Joins Verseon's Scientific Advisory Board
Pioneering expert in membrane protein structure and function to advise Verseon on its platform and pipeline development
November 9, 2023
AI in Drug Discovery: Synthetic Data, Explainable AI, and Beyond
Verseon CEO Adityo Prakash speaks at Frontiers Health 2023
November 8, 2023
AI Drug Discovery... Who Owns the Patents?
Verseon's Ed Ratner comments on the questions of when and whether to patent AI implementations
October 23, 2023
California-based Verseon is Spearheading the New approach to Drug Development
The emergence of completely new drugs to tackle some of the world’s most prevalent diseases have been few and far between. But that could be about to change. Verseon creates drugs atom by atom, using a proprietary technology platform that goes far beyond just the application of AI
September 15, 2023
Faster, better, more productive
[Verseon’s] models for “de novo molecular design” can figure out which molecular structures are most likely to do which things, and they build accordingly
September 13, 2023
Digital CxO Podcast Ep. 50 - AI for the Pharmaceutical Industry
Verseon is changing how completely new medicines get designed, what we can treat and how well we treat them.... The company designs, atom by atom, completely novel drugs that you cannot find with any other method.... They hold the promise of completely changing the standard of care for the diseases they address because of how unique their therapeutic profiles are
July 24, 2023
Why AI alone won't resolve drug discovery challenges
"When it comes to drug discovery, AI has a data problem with which the pharmaceutical industry has not yet come to terms"
June 21, 2023
Exploring New Chemical Space for the Treatments of Tomorrow
We've seen the benefits of exploring entirely novel chemical entities... We are now entering an exciting new era in drug discovery and development with immense implications for human health.
June 1, 2023
AI in drug development: A reality check
"Existing data... is a small, little tiny pittance compared to the total number of possibilities that one could explore... Asking A.I. trained on that data to suddenly change everything... is more than just asking a lot. It's not possible."
May 25, 2023
Unlocking a Universe of Drug Candidates
Verseon's hybrid physics- and AI-based platform reveals possibilities far outside the Pharma industry's compound libraries
May 4, 2023
Dreaming Up Drugs No One Has Ever Seen
Verseon's physics- and AI-based drug discovery platform is expanding the frontiers of medicine
FEBRUARY 15, 2023
Disruptors Plan a New Dawn for Healthcare Technology
The Business Influencer describes how Verseon’s drug discovery platform is systematically tackling humanity’s major killers
FEBRUARY 3, 2023
What Will it Take for AI to Live Up to its Hype?
Adityo Prakash, CEO of Verseon, discusses how the data currently available to the pharma industry and other challenges limit AI’s ability to help discover novel drugs
JANUARY 31, 2023
Small Data, Big Ambitions
Verseon's combination of physics-based molecular modeling and Extreme Machine Learning promises multiple treatment options for patients who currently have none
JANUARY 11, 2023
Verseon’s New Oral Anticoagulant Drug Candidates Demonstrate Lower Bleeding Risk
Verseon has developed candidates for a next-generation oral anticoagulant that have the potential to prevent unwanted clots while preserving the body’s ability to stop excessive bleeding
December 15, 2022
Preventing Strokes and Heart Attacks Doesn’t Have to Come with the Risk of Life-threatening Bleeding
Verseon’s scientific journey to highly promising therapeutic candidates for cardiovascular disease appears in European Journal of Medicinal Chemistry
DECEMBER 14, 2022
Is AI just hype or a real revolution in pharma? It’s complicated
Verseon's CEO Adityo Prakash discusses the challenges and opportunities facing AI in drug discovery
NOVEMBER 17, 2022
Why there's more to life than making it to a ripe old age
The National describes how Verseon's drug programs place the company at the vanguard of preventing the chronic diseases and disabilities of ageing
NOVEMBER 4, 2022
Verseon Acquires Edammo to Deepen Drug Discovery Approach
Verseon deepens its AI capabilities by acquiring company focused on analyzing the "Small and Wide Data" typical in drug discovery
October 18, 2022
Exploring the Uncharted Chemical Universe for New Medicines
David Kita, Verseon’s CSO, shares his views on the future of computational drug discovery
September 28, 2022
No, AI by Itself Probably Won't Revolutionize Drug Development
Alphabet's DeepMind admits they can't predict drug-protein interactions; "It's just hype," says Adityo Prakash, Verseon's CEO
September 24, 2022
Verseon's PKIs to Battle Diabetic Vision Loss
Verseon's scientists consistently find unique drug candidates that have never been designed or synthesised by anyone else
September 22, 2022
Verseon's HAE Drug Candidates in Focus
Verseon's oral drug candidates will offer an alternative to injections for a rare but potentially fatal condition
September 16, 2022
Verseon Gains European Patent Protection for Potential Sight and Life-Saving Treatments
"These novel compounds ... could help hundreds of millions of people around the world," says David Kita, Verseon's CSO
September 7, 2022
Challenges Facing AI in Drug Discovery
Adityo Prakash, Verseon’s CEO, discusses the way forward
September 1, 2022
Why AI Alone Won’t Solve Drug Discovery
“People are saying, ‘Oh, AI will solve everything.’ It’s just hype,” says Adityo Prakash, Verseon's CEO to Datanami's Alex Woodie
August 30, 2022
Overcoming the Limitations of Drug Discovery AI
"For the foreseeable future, there will simply not be enough experimental binding data available for AI models to reliably predict truly novel, potent, and selective small molecule drug candidates."
July 11, 2022
BioSpace Says Verseon Is "Changing the Paradigm of Drug Discovery"
“What sets Verseon apart is its use of molecular physics modeling to enable the atomic-level engineering of new molecules.”
MAY 03, 2022
Why AI Alone Cannot Find Tomorrow’s Medicines
“AI is good at interpolating features within the bounds of a well-explored pool of training data but unable to make useful extrapolations far outside it."
April 27, 2022
Impact Wealth Magazine Hails Verseon as the Company Redefining Delay, Prevention, and Treatment of Disease
"Between its regulated pharmaceuticals and consumer healthspan products, Verseon ... will likely transform twenty-first century medicine and touch the lives of everyone on the planet."
April 11, 2022
Verseon’s Kevin Short Speaks with Pharmaceutical Technology Magazine About the Utility of Data and AI in Medicinal Chemistry
“As we collect much larger and more complex data sets from increasingly advanced functionally predictive assays, machine-learning tools could potentially make medicinal chemistry operations more efficient.”
April 2, 2022
MarkTechPost Features Verseon in Latest Issue of AI in Healthcare Magazine
Interview with Verseon CEO Adityo covers challenges in small-molecule drug discovery and what Verseon is doing to address them, spanning advances in fundamental science and AI.
March 30, 2022
Dr. Sangtae Kim to Lead Verseon’s New AI and Data-Science Initiative as CTO
Accomplished veteran of pharmaceutical industry and academia joins Verseon's senior executive team
January 12, 2022
Verseon's Anirban Datta Explains Challenges for Current Antiviral Drugs and Vaccines
Company suggests focusing on host-centric approach for a new class of antivirals as a lasting solution to combat SARS-CoV-2 and other viruses
January 11, 2022
Verseon's Unique Physics- & AI-based Platform Highlighted in Nano Magazine Feature on the Future of Drug Discovery
Comprehensive drug design & development platform praised for its ability to systematically generate multiple chemically distinct candidates in each program
December 15, 2021
Verseon Nominates Primary Drug Candidate for Oral Prophylactic Treatment of the Most Common Cause of Diabetic Vision Loss
Precision-engineered by Verseon's unique computational platform, VE-4840 advances as primary development candidate after key in vivo and preliminary toxicology studies
August 5, 2021
Verseon's Diabetic Retinopathy Drug Candidate Hits Key Milestone, Demonstrating Significant Reduction of Retinal Vascular Permeability
An in vivo efficacy study strongly suggests that drug candidate VE-4840 mitigates damage to retinal blood vessels—a milestone in establishing the compound’s effectiveness as an oral treatment of diabetic retinopathy
May 5, 2021
Verseon's Patent Portfolio Continues to Grow as Platform Produces New Family of Novel Potential Drugs
Receipt of European patent for innovative thrombin inhibitors underscores the power of Verseon's systematic drug design technologies
January 12, 2021
Wellcome and Allergan Veteran Trevor M. Jones Joins Verseon’s Scientific Advisory Board
New addition to company's advisors brings extensive drug research and development experience to the role
November 30, 2020
Verseon Announces Program Targeting Aggressive Metastatic Cancer
The company's third cancer program targets an overexpressed protease on the surface of many solid-tumor cancer cells
September 30, 2020
Journal Thrombosis Research Publishes Peer Reviewed Results Demonstrating Efficacy and Reduced Bleeding Risk for Verseon Anticoagulant VE-1902
New class of anticoagulant drug candidates demonstrates a unique combination of efficacy with lower bleeding in preclinical testing
April 20, 2020
Want to get in touch?
Continue to
Contact
April 14, 2025
